Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

anti-COVID drug

- PMLiVE

Merck announces agreement with US government to reduce prices of prescription medication

The pharma company will invest more than $70bn in the US to boost production and innovation

- PMLiVE

Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

- PMLiVE

Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

- PMLiVE

Merck and Blackstone agree on funding for cancer protein antibody

The funding will support late-stage clinical development of the investigational antibody-drug conjugate

- PMLiVE

David Weinreich appointed as Merck’s head of R&D and CMO for healthcare

Weinreich brings clinical development and venture capital experience to the role

- PMLiVE

AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

Innovative Trials

- PMLiVE

Invivyd working with FDA towards potential Biologics License Application for COVID-19

The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

- PMLiVE

FDA approves Pfizer and BioNTech’s jab for COVID-19

Globally, five billion doses of the companies’ vaccine have been distributed

- PMLiVE

MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

- PMLiVE

Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

Merck to expand respiratory disease portfolio with $10bn Verona acquisition

The deal includes a drug approved in the US for chronic obstructive pulmonary disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links